Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients

Journal of Viral Hepatitis

Volumn 19, Issue 10, 2012, Pages 685-693

  Suarez Zarracina T ^a   Valle Garay, E ^a   Collazos, J ^b   Montes, A H ^a   Carcaba V ^a   Carton, J A ^a   Asensi, V ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

Author keywords

antiretrovirals; hepatitis C virus; human immunodeficiency virus; liver fibrosis; matrix metalloproteases; transition elastometry

Indexed keywords

ATAZANAVIR; COLLAGENASE 3; DIDANOSINE; EMTRICITABINE; FOSAMPRENAVIR; GELATINASE A; GELATINASE B; INDINAVIR; INTERSTITIAL COLLAGENASE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEUTROPHIL COLLAGENASE; SAQUINAVIR; STAVUDINE; STROMELYSIN; STROMELYSIN 2; TENOFOVIR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; ZALCITABINE; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CAUCASIAN; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSIENT ELASTOMETRY; VIRUS LOAD;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; DIDANOSINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASES; MICROARRAY ANALYSIS; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES; VIRAL LOAD;

EID: 84866254505     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01596.x     Document Type: Article

References (38)

1. Martín-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study study. Clin Infect Dis 2004; 38: 128-133.
2. Cartõn JA, Collazos J, de la Fuente B, et al. Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV. Antiviral Ther 2011; 16: 27-35.
3. Núñez M,. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44 (Suppl. 1): S132-139.
4. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372.
5. Maida I, Núñez M, Ríos MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42: 177-182.
6. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 2: 187-192.
7. Merchante N, Pérez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010; 15: 753-763.
8. Macías J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767-774.
9. Pineda JA, Macías J,. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother 2005; 55: 417-419.
10. Berenguer J, Bellõn JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46: 137-143.
11. Macías J, Mira JA, Lõpez-Cortés LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11: 839-846.
12. Pineda JA, Pérez-Elías MJ, Peña JM, Rodríguez-Alcantara F, Fosamprenavir Expanded Access Program Group. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin.Trials 2008; 9: 309-313.
13. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
14. Macías J, Recio E, Vispo E, et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol 2008; 49: 916-922.
15. Consolo M, Amoroso A, Spandidos DA, Mazzarino MC,. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease. Int J Mol Med 2009; 24: 143-152.
16. Larrousse M, Laguno M, Segarra M, et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 46: 304-311.
17. Macías J, Mira J, Gilabert I, et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2011; 12: 14-21.
18. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16: 605-613.
19. Lichtenstein KA,. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395-400.
20. Asensi V, Martin-Roces E, Collazos J, et al. Association between physical and echographic fat thickness assessments and a lipodystrophy grading scale in lypodystrophic HIV patients. Practical implications. AIDS Res Human Retroviruses 2006; 22: 830-836.
21. Vispo E, Barreiro P, Del Valle J, et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther 2009; 14: 187-193.
22. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
23. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.
24. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36.
25. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
26. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
27. Montes AH, Valle-Garay E, Suarez-Zarracina T, et al. The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS 2010; 24: 2499-2506.
28. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18: 11-16.
29. Collazos J, Carton JA, Asensi V,. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus. Curr HIV Res 2011; 9: 339-345.
30. Lewis W, Day BJ, Copeland WC,. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2: 812-822.
31. Choi J, Liu RM, Kundu RK, et al. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem 2000; 275: 3693-3698.
32. Barbaro G, Di Lorenzo G, Soldini M, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol 1996; 91: 2569-2573.
33. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626-635.
34. Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997; 26: 574-583.
35. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H,. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999; 14: 38-45.
36. Lichtinghagen R, Michels D, Haberkorn CI, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 2001; 34: 239-247.
37. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R,. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316: 71-81.
38. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Tanus-Santos JE,. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 2009; 9: 265-73.